{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T07:34:50Z","timestamp":1790408090689,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s11060-022-03995-9","type":"journal-article","created":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T19:03:46Z","timestamp":1648839826000},"page":"511-521","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Gyriform infiltration as imaging biomarker for molecular glioblastomas"],"prefix":"10.1007","volume":"157","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4586-1264","authenticated-orcid":false,"given":"Emmanuel","family":"Mesny","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Barritault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Izquierdo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Poncet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"d\u2019Hombres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Guyotat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Jouanneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana","family":"Ameli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Honnorat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Meyronet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Ducray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,1]]},"reference":[{"key":"3995_CR1","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P et al (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23:1231\u20131251. https:\/\/doi.org\/10.1093\/neuonc\/noab106","journal-title":"Neuro Oncol"},{"key":"3995_CR2","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/bpa.12832","volume":"30","author":"DN Louis","year":"2020","unstructured":"Louis DN, Wesseling P, Aldape K et al (2020) cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. Brain Pathol 30:844\u2013856. https:\/\/doi.org\/10.1111\/bpa.12832","journal-title":"Brain Pathol"},{"key":"3995_CR3","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s00401-018-1905-0","volume":"136","author":"D Stichel","year":"2018","unstructured":"Stichel D, Ebrahimi A, Reuss D et al (2018) Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma. Acta Neuropathol 136:793\u2013803. https:\/\/doi.org\/10.1007\/s00401-018-1905-0","journal-title":"Acta Neuropathol"},{"key":"3995_CR4","doi-asserted-by":"publisher","first-page":"E448","DOI":"10.1093\/neuros\/nyy513","volume":"85","author":"C Izquierdo","year":"2019","unstructured":"Izquierdo C, Barritault M, Poncet D et al (2019) Radiological characteristics and natural history of adult IDH-wildtype astrocytomas with TERT promoter mutations. Neurosurgery 85:E448\u2013E456. https:\/\/doi.org\/10.1093\/neuros\/nyy513","journal-title":"Neurosurgery"},{"key":"3995_CR5","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s00401-010-0777-8","volume":"120","author":"P Metellus","year":"2010","unstructured":"Metellus P, Coulibaly B, Colin C et al (2010) Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol 120:719\u2013729. https:\/\/doi.org\/10.1007\/s00401-010-0777-8","journal-title":"Acta Neuropathol"},{"key":"3995_CR6","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s11060-018-03034-6","volume":"141","author":"TA Juratli","year":"2019","unstructured":"Juratli TA, Tummala SS, Riedl A et al (2019) Radiographic assessment of contrast enhancement and T2\/FLAIR mismatch sign in lower grade gliomas: correlation with molecular groups. J Neurooncol 141:327\u2013335. https:\/\/doi.org\/10.1007\/s11060-018-03034-6","journal-title":"J Neurooncol"},{"key":"3995_CR7","first-page":"vdaa04","volume":"2","author":"DI van Lent","year":"2020","unstructured":"van Lent DI, van Baarsen KM, Snijders TJ, Robe PAJT (2020) Radiological differences between subtypes of WHO 2016 grade II-III gliomas: a systematic review and meta-analysis. Neuro Oncol Adv 2:vdaa04","journal-title":"Neuro Oncol Adv"},{"key":"3995_CR8","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/nm.2682","volume":"18","author":"C Choi","year":"2012","unstructured":"Choi C, Ganji SK, DeBerardinis RJ et al (2012) 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med 18:624\u2013629. https:\/\/doi.org\/10.1038\/nm.2682","journal-title":"Nat Med"},{"key":"3995_CR9","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1093\/neuonc\/noy048","volume":"20","author":"MPG Broen","year":"2018","unstructured":"Broen MPG, Smits M, Wijnenga MMJ et al (2018) The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p\/19q-intact lower-grade glioma: a validation study. Neuro Oncol 20:1393\u20131399. https:\/\/doi.org\/10.1093\/neuonc\/noy048","journal-title":"Neuro Oncol"},{"key":"3995_CR10","doi-asserted-by":"publisher","first-page":"6078","DOI":"10.1158\/1078-0432.CCR-17-0560","volume":"23","author":"SH Patel","year":"2017","unstructured":"Patel SH, Poisson LM, Brat DJ et al (2017) T2-FLAIR mismatch, an imaging biomarker for IDH and 1p\/19q status in lower-grade gliomas: A TCGA\/TCIA project. Clin Cancer Res 23:6078\u20136085. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0560","journal-title":"Clin Cancer Res"},{"key":"3995_CR11","doi-asserted-by":"publisher","first-page":"vdaa004","DOI":"10.1093\/noajnl\/vdaa004","volume":"2","author":"M Foltyn","year":"2020","unstructured":"Foltyn M, Nieto Taborda KN, Neuberger U et al (2020) T2\/FLAIR-mismatch sign for noninvasive detection of IDH-mutant 1p\/19q non-codeleted gliomas: validity and pathophysiology. Neuro Oncol Adv 2:vdaa004","journal-title":"Neuro Oncol Adv"},{"key":"3995_CR12","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1093\/neuonc\/now274","volume":"19","author":"D Meyronet","year":"2017","unstructured":"Meyronet D, Esteban-Mader M, Bonnet C et al (2017) Characteristics of H3 K27M-mutant gliomas in adults. Neuro Oncol 19:1127\u20131134. https:\/\/doi.org\/10.1093\/neuonc\/now274","journal-title":"Neuro Oncol"},{"key":"3995_CR13","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1212\/WNL.0000000000000814","volume":"83","author":"M Labussi\u00e8re","year":"2014","unstructured":"Labussi\u00e8re M, Boisselier B, Mokhtari K et al (2014) Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes. Neurology 83:1200\u20131206. https:\/\/doi.org\/10.1212\/WNL.0000000000000814","journal-title":"Neurology"},{"key":"3995_CR14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1093\/neuonc\/nou158","volume":"17","author":"M Simon","year":"2015","unstructured":"Simon M, Hosen I, Gousias K et al (2015) TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas. Neuro Oncol 17:45\u201352. https:\/\/doi.org\/10.1093\/neuonc\/nou158","journal-title":"Neuro Oncol"},{"key":"3995_CR15","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2307\/2529310","volume":"33","author":"JR Landis","year":"1977","unstructured":"Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159\u2013174","journal-title":"Biometrics"},{"key":"3995_CR16","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/neuonc\/noz200","volume":"22","author":"CMS Tesileanu","year":"2020","unstructured":"Tesileanu CMS, Dirven L, Wijnenga MMJ et al (2020) Survival of diffuse astrocytic glioma, IDH1\/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-now criteria. Neuro Oncol 22:515\u2013523. https:\/\/doi.org\/10.1093\/neuonc\/noz200","journal-title":"Neuro Oncol"},{"key":"3995_CR17","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s11060-020-03677-4","volume":"152","author":"D Lee","year":"2021","unstructured":"Lee D, Riestenberg RA, Haskell-Mendoza A, Bloch O (2021) Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV: a single-institution case series and review. J Neurooncol 152:89\u201398. https:\/\/doi.org\/10.1007\/s11060-020-03677-4","journal-title":"J Neurooncol"},{"key":"3995_CR18","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1093\/neuonc\/nox132","volume":"20","author":"K Aoki","year":"2018","unstructured":"Aoki K, Nakamura H, Suzuki H et al (2018) Prognostic relevance of genetic alterations in diffuse lower-grade gliomas. Neuro Oncol 20:66\u201377. https:\/\/doi.org\/10.1093\/neuonc\/nox132","journal-title":"Neuro Oncol"},{"key":"3995_CR19","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s11060-016-2193-y","volume":"129","author":"A Lasocki","year":"2016","unstructured":"Lasocki A, Gaillard F, Tacey MA et al (2016) The incidence and significance of multicentric noncontrast-enhancing lesions distant from a histologically-proven glioblastoma. J Neurooncol 129:471\u2013478. https:\/\/doi.org\/10.1007\/s11060-016-2193-y","journal-title":"J Neurooncol"},{"key":"3995_CR20","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jocn.2020.11.050","volume":"85","author":"A Benouaich-Amiel","year":"2021","unstructured":"Benouaich-Amiel A, Khasminsky V, Gal O et al (2021) Multicentric non-enhancing lesions in glioblastoma: a retrospective study. J Clin Neurosci 85:20\u201326. https:\/\/doi.org\/10.1016\/j.jocn.2020.11.050","journal-title":"J Clin Neurosci"},{"key":"3995_CR21","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/1754-9485.12421","volume":"60","author":"A Lasocki","year":"2016","unstructured":"Lasocki A, Gaillard F, Tacey M et al (2016) Incidence and prognostic significance of non-enhancing cortical signal abnormality in glioblastoma. J Med Imaging Radiat Oncol 60:66\u201373. https:\/\/doi.org\/10.1111\/1754-9485.12421","journal-title":"J Med Imaging Radiat Oncol"},{"key":"3995_CR22","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s11060-021-03720-y","volume":"152","author":"SH Patel","year":"2021","unstructured":"Patel SH, Batchala PP, Muttikkal TJE et al (2021) Fluid attenuation in non-contrast-enhancing tumor (nCET): an MRI marker for isocitrate dehydrogenase (IDH) mutation in glioblastoma. J Neurooncol 152:523\u2013531. https:\/\/doi.org\/10.1007\/s11060-021-03720-y","journal-title":"J Neurooncol"},{"key":"3995_CR23","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jocn.2017.09.007","volume":"47","author":"A Lasocki","year":"2018","unstructured":"Lasocki A, Gaillard F, Tacey M et al (2018) Morphologic patterns of noncontrast-enhancing tumor in glioblastoma correlate with IDH1 mutation status and patient survival. J Clin Neurosci 47:168\u2013173. https:\/\/doi.org\/10.1016\/j.jocn.2017.09.007","journal-title":"J Clin Neurosci"},{"key":"3995_CR24","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/j.ijrobp.2009.09.018","volume":"78","author":"MT Milano","year":"2010","unstructured":"Milano MT, Okunieff P, Donatello RS et al (2010) Patterns and timing of recurrence after temozolomide-based chemoradiation for glioblastoma. Int J Radiat Oncol Biol Phys 78:1147\u20131155. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.09.018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3995_CR25","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1200\/JCO.2008.19.4969","volume":"27","author":"AA Brandes","year":"2009","unstructured":"Brandes AA, Tosoni A, Franceschi E et al (2009) Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status. J Clin Oncol 27:1275\u20131279. https:\/\/doi.org\/10.1200\/JCO.2008.19.4969","journal-title":"J Clin Oncol"},{"key":"3995_CR26","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jocn.2019.07.065","volume":"68","author":"L Lahmi","year":"2019","unstructured":"Lahmi L, Idbaih A, Rivin Del Campo E et al (2019) Whole brain radiotherapy with concurrent temozolomide in multifocal and\/or multicentric newly diagnosed glioblastoma. J Clin Neurosci 68:39\u201344. https:\/\/doi.org\/10.1016\/j.jocn.2019.07.065","journal-title":"J Clin Neurosci"},{"key":"3995_CR27","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.ijrobp.2007.03.045","volume":"69","author":"TN Showalter","year":"2007","unstructured":"Showalter TN, Andrel J, Andrews DW et al (2007) Multifocal glioblastoma multiforme: prognostic factors and patterns of progression. Int J Radiat Oncol Biol Phys 69:820\u2013824. https:\/\/doi.org\/10.1016\/j.ijrobp.2007.03.045","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3995_CR28","first-page":"333","volume":"34","author":"HJ Scherer","year":"1938","unstructured":"Scherer HJ (1938) Structural development in gliomas. Am J Cancer 34:333\u2013351","journal-title":"Am J Cancer"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-022-03995-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-022-03995-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-022-03995-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T07:09:24Z","timestamp":1651734564000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-022-03995-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,1]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["3995"],"URL":"https:\/\/doi.org\/10.1007\/s11060-022-03995-9","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,1]]},"assertion":[{"value":"2 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors report no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}